Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype.

Rauchschwalbe SK, Zühlsdorf MT, Wensing G, Kuhlmann J.

Int J Clin Pharmacol Ther. 2004 Feb;42(2):73-7.

PMID:
15180166
2.

Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype.

Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR.

Hum Mutat. 2000 Oct;16(4):297-306. Review.

PMID:
11013440
3.

[From gene to disease; unconjugated hyperbilirubinemia: Gilbert's syndrome and Crigler-Najjar types I and II].

Drenth JP, Peters WH, Jansen JB.

Ned Tijdschr Geneeskd. 2002 Aug 10;146(32):1488-90. Review. Dutch.

PMID:
12198827
4.

Molecular genetic basis of Gilbert's syndrome.

Burchell B, Hume R.

J Gastroenterol Hepatol. 1999 Oct;14(10):960-6. Review.

PMID:
10530490
5.

Gilbert syndrome: the UGT1A1*28 promoter polymorphism as a biomarker of multifactorial diseases and drug metabolism.

Gil J, Sąsiadek MM.

Biomark Med. 2012 Apr;6(2):223-30. doi: 10.2217/BMM.12.4. Review.

PMID:
22448797
6.

Drug-mediated toxicity caused by genetic deficiency of UDP-glucuronosyltransferases.

Burchell B, Soars M, Monaghan G, Cassidy A, Smith D, Ethell B.

Toxicol Lett. 2000 Mar 15;112-113:333-40. Review.

PMID:
10720749
7.

[Inherited disorders of bilirubin metabolism].

Rossi F, Francese M, Iodice RM, Falcone E, Vetrella S, Punzo F, De Vita S, Perrotta S.

Minerva Pediatr. 2005 Apr;57(2):53-63. Review. Italian.

PMID:
15985997
8.

Pharmacogenetics of Gilbert's syndrome.

Strassburg CP.

Pharmacogenomics. 2008 Jun;9(6):703-15. doi: 10.2217/14622416.9.6.703. Review.

PMID:
18518849
9.

Function, genetic polymorphism, and transcriptional regulation of human UDP-glucuronosyltransferase (UGT) 1A1.

Sugatani J.

Drug Metab Pharmacokinet. 2013;28(2):83-92. Epub 2012 Oct 23. Review.

10.

Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin.

Schwertner HA, Vítek L.

Atherosclerosis. 2008 May;198(1):1-11. doi: 10.1016/j.atherosclerosis.2008.01.001. Epub 2008 Mar 17. Review.

PMID:
18343383
11.

Role of extrahepatic UDP-glucuronosyltransferase 1A1: Advances in understanding breast milk-induced neonatal hyperbilirubinemia.

Fujiwara R, Maruo Y, Chen S, Tukey RH.

Toxicol Appl Pharmacol. 2015 Nov 15;289(1):124-32. doi: 10.1016/j.taap.2015.08.018. Epub 2015 Sep 2. Review.

12.

Bilirubin, platelet activation and heart disease: a missing link to cardiovascular protection in Gilbert's syndrome?

Kundur AR, Singh I, Bulmer AC.

Atherosclerosis. 2015 Mar;239(1):73-84. doi: 10.1016/j.atherosclerosis.2014.12.042. Epub 2014 Dec 24. Review.

PMID:
25576848
13.

The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions.

Marques SC, Ikediobi ON.

Hum Genomics. 2010 Apr;4(4):238-49. Review.

14.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.

Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, Guillemette C, Lennox JL, Whirl-Carrillo M, Brummel SS, Ratain MJ, Klein TE, Schackman BR, Caudle KE, Haas DW; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2016 Apr;99(4):363-9. doi: 10.1002/cpt.269. Epub 2015 Nov 9. Review.

15.

UGT1A1 Mediated Drug Interactions and its Clinical Relevance.

Goon CP, Wang LZ, Wong FC, Thuya WL, Ho PC, Goh BC.

Curr Drug Metab. 2016;17(2):100-6. Review.

PMID:
26526830

Supplemental Content

Support Center